Empagliflozin (Jardiance) for Diabetes, Heart & Kidney Protection — Weight & Metabolism
SGLT2 inhibitor with landmark cardiovascular and kidney outcome data from EMPA-REG OUTCOME, EMPEROR, and EMPA-KIDNEY trials.
Overview
Empagliflozin is an SGLT2 inhibitor FDA-approved for type 2 diabetes, heart failure (HFrEF and HFpEF), and chronic kidney disease. The EMPA-REG OUTCOME trial (n=7,020, median 3.1 years) demonstrated 14% reduction in MACE (HR 0.86), a remarkable 38% reduction in cardiovascular death (HR 0.62), and 35% reduction in heart failure hospitalization. EMPEROR-Reduced (HFrEF) showed 25% reduction in CV death/HF hospitalization regardless of diabetes status. EMPEROR-Preserved extended benefits to HFpEF (21% reduction). EMPA-KIDNEY (n=6,609) demonstrated 28% reduction in kidney disease progression (HR 0.72) in patients with eGFR as low as 20. HbA1c reduction of 0.7-0.8% with 2-3kg weight loss. PMID: 26378978, 32865377, 34449189, 36331190.
Indications
- Type 2 diabetes mellitus as monotherapy or combination therapy
- Heart failure with reduced ejection fraction (HFrEF) regardless of diabetes status
- Heart failure with preserved ejection fraction (HFpEF)
- Chronic kidney disease with risk of progression (eGFR >=20)
- Cardiovascular risk reduction in T2DM with established CVD
Mechanism of Action
SGLT2 transporters in kidney proximal tubule reabsorb ~90% of filtered glucose (~180g/day); upregulated in diabetes, worsening hyperglycemia
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Empagliflozin (Jardiance) | 10 mg | Once daily in the morning | Starting and standard dose for T2DM; may increase to 25mg for additional glycemic control |
| Empagliflozin (Jardiance) | 25 mg | Once daily in the morning | Maximum dose; ~0.1% additional HbA1c reduction vs 10mg |
| Empagliflozin (Jardiance) | 10 mg | Once daily | Fixed dose for HFrEF and HFpEF; no titration needed |
| Empagliflozin (Jardiance) | 10 mg | Once daily | EMPA-KIDNEY dose; can initiate if eGFR >=20; continue if eGFR drops below |
Safety & Contraindications
- FDA-approved since 2014 with extensive cardiovascular and renal outcome trial data
- Genital mycotic infections most common (5-10%): candidal vulvovaginitis in women, balanitis in men
- Risk of euglycemic diabetic ketoacidosis (eDKA): hold before surgery, during acute illness, or prolonged fasting
- May cause volume depletion: use caution with loop diuretics; monitor for orthostatic hypotension in elderly
- Fournier's gangrene: rare but serious necrotizing fasciitis of perineum (FDA warning); seek immediate care for genital pain/tenderness
- Not recommended for type 1 diabetes; limited glycemic benefit when eGFR <30 but cardiorenal benefits persist